Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2023-03-22 Regulatory Filings
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Health economic model identifies GCAL® as a cost-effective biomarker
Regulatory Filings Classification · 85% confidence The document is a scientific research paper or white paper evaluating the health economic impact of a specific medical diagnostic product (GCAL® calprotectin immunoassay). It contains academic authors, methodology, results, and a conclusion. It does not fit any of the financial filing categories (such as 10-K, IR, or ER) as it is not a corporate financial report, nor is it a regulatory announcement. Since it does not fit into the specific financial categories provided, it falls under the 'Regulatory Filings' (RNS) category as the designated fallback for miscellaneous documents. FY 2020
2023-03-22 English
Health economic model identifies GCAL® as a cost-effective biomarker
Report Publication Announcement Classification · 98% confidence The document is a short announcement dated March 22, 2023, from Gentian Diagnostics ASA regarding the presentation of a health economic model study on their GCAL® Calprotectin Immunoassay at a symposium. It summarizes key findings (cost savings, mortality reduction) and explicitly states, "For further information please see the enclosed study poster." Given the short length (2481 characters) and the nature of announcing the availability of external material (a study poster), this fits the criteria for a Report Publication Announcement (RPA) rather than the full report itself (like an ER or IR).
2023-03-22 English
Financial calendar
Report Publication Announcement Classification · 98% confidence The document is titled 'Financial calendar' and lists future dates for various corporate events, including the 'Half-yearly Report', 'Annual Report', 'Annual General Meeting', and 'Quarterly Report - Q1/Q3'. It also notes a change in the date for the Q1 2023 report. This document is purely informational regarding the schedule of future corporate disclosures, not the disclosure itself. Since there is no specific category for a 'Financial Calendar', and it is a general announcement about future reporting events, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially 'RPA' if it were announcing the publication of a report, but here it is announcing the *dates* of future reports. Given the options, RNS is the most appropriate fallback for a general schedule announcement that doesn't fit the specific report types listed.
2023-03-17 English
Fourth quarter and full year 2022 report
Investor Presentation Classification · 98% confidence The document is titled 'Q4 22 Presentation' and contains detailed financial highlights for the fourth quarter of 2022 (4Q22), including sales figures, gross margin, EBITDA, balance sheet data, and management team introductions. This structure—a presentation summarizing period results—is characteristic of an Investor Presentation (IP). It is not a full regulatory filing like a 10-K, nor is it just a brief press release announcing results (ER). Since it is a detailed presentation format covering strategy, products, and financials for a specific period, 'IP' is the most appropriate classification.
2023-02-16 English
Fourth quarter and full year 2022 report
Earnings Release Classification · 99% confidence The document text contains detailed financial highlights for 'Fourth quarter 2022' and 'Full year 2022', including sales revenue, EBITDA figures, operational summaries, product development updates (NT-proBNP, GCAL), and a long-term outlook. The structure, content (financial metrics, operational review, forward-looking statements), and explicit mention of Q4 results strongly indicate this is a comprehensive report covering a specific fiscal period. Since it covers the full year and the fourth quarter, it is most likely an Annual Report (10-K) or a comprehensive Interim/Quarterly Report (IR). Given the depth and the inclusion of full-year figures alongside Q4, it aligns best with the scope of a comprehensive periodic report. If this were a press release announcing results, it would be an Earnings Release (ER). However, the level of detail provided (including detailed tables and strategy deep dives) suggests it is more than just the initial highlights release. In the context of standard SEC filings, a document detailing full-year performance is typically a 10-K. If it were a non-US company's equivalent, it often maps to the most comprehensive report available. Since it covers the full year and is highly detailed, I will classify it as the most comprehensive annual report type available, 10-K, although it could also be a very detailed IR if the company only reports semi-annually and this is the year-end summary. Given the 'Fourth quarter 2022 highlights' and 'Full year sales revenue' are central, it functions as the primary annual financial disclosure. Q4 2022
2023-02-16 English
Fourth quarter and full year 2022 report
Earnings Release Classification · 100% confidence The document explicitly states it announces the 'Fourth quarter and full year 2022 report' and provides key financial highlights (Sales, EBITDA) for Q4 2022 and the full year. This structure—a brief announcement summarizing key figures followed by management commentary and webcast details—is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results. It is too brief and summary-focused to be a full Interim Report (IR) or Annual Report (10-K). Since it contains the core results announcement, ER is the most appropriate classification. Q4 2022
2023-02-16 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.